Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 4/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 12/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19464606 | 0.85 | SMPD1 (0.35) | SMPD1HRH4HRH3GBA1DGAT1 | |
| SCHEMBL20375449 | 0.84 | SMPD1 (0.48) | SMPD1HRH4HRH3GBA1 | |
| SCHEMBL20878340 | 0.82 | SMPD1 (0.46) | SMPD1HRH4HRH3GBA1 | |
| SCHEMBL18492361 | 0.79 | HRH4 (0.36) | SMPD1HRH4HRH3DGAT1 | |
| SCHEMBL19245614 | 0.77 | HRH4 (0.34) | SMPD1HRH4HRH3GBA1 | |
| SCHEMBL22667288 | 0.73 | IDO1 (0.36) | HRH4HRH3 | |
| SCHEMBL13453642 | 0.73 | SMPD1 (0.41) | SMPD1HRH4HRH3GBA1 | |
| SCHEMBL24060950 | 0.73 | SMPD1 (0.36) | SMPD1HRH4HRH3GBA1DGAT1 | |
| SCHEMBL23265136 | 0.72 | SMPD1 (0.48) | SMPD1HRH4HRH3GBA1 | |
| SCHEMBL10080835 | 0.71 | SMPD1 (0.50) | SMPD1HRH4HRH3GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | SMPD1 4661/4885HRH4 4475/4885HRH3 4489/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | SMPD1 4661/4885HRH4 4475/4885HRH3 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.